Job overview
Due to the internal promotion of the current postholder, an exciting opportunity has arisen for a highly motivated and enthusiastic clinical pharmacist with excellent clinical and interpersonal skills to support a high quality service to the Inflammatory Bowel Disease (IBD) Service, within our Gastrointestinal (GI) Services Division.
You will work as part of the IBD multidisciplinary team, delivering the highest quality service for both inpatients and outpatients, working closely with the IBD consultants, clinical fellows, clinical nurse specialists, and other healthcare professionals.
You will form part of a virtual biologics clinic, using your independent prescribing skills to streamline the initiation of therapy for new patients, and provide ongoing follow-up review, with therapeutic drug monitoring where relevant.
You will also participate in weekly MDT meetings for new and existing patients, liaise with GPs and pharmacists in general practice and community, and develop shared care arrangements in order to ensure patients receive the maximum benefit from therapy with the minimum of complications. You will support an IBD advice line for patients, providing a point of contact for patients with queries relating to their medicines or homecare arrangements.
Main duties of the job
You will form part of a virtual biologics clinic, using your independent prescribing skills to streamline the initiation of therapy for new patients, and provide ongoing follow-up review, with therapeutic drug monitoring where relevant.
You will also participate in weekly MDT meetings for new and existing patients, liaise with GPs and pharmacists in general practice and community, and develop shared care arrangements in order to ensure patients receive the maximum benefit from therapy with the minimum of complications. You will support an IBD advice line for patients, providing a point of contact for patients with queries relating to their medicines or homecare arrangements.
The UCLH IBD Service has a large number of patients receiving biologics. Some are managed through homecare arrangements, whilst others receive regular infusions through our Infusion Clinic, based in University College Hospital. You will be responsible for ensuring prescriptions are screened and dispensed in advance using our electronic health record system, Epic. You will aim to ensure that all patients are registered on Blueteq®, that yearly follow-ups are documented, and that the data requirements of our commissioners are met. Where possible, you will work to develop and enhance our existing systems, particularly where efficiency and productivity can be improved through Epic.
Continued below....
Working for our organisation
University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.
We provide first-class acute and specialist services across eight sites:
University College Hospital (incorporating the Elizabeth Garrett Anderson Wing)
National Hospital for Neurology and Neurosurgery
Royal National ENT and Eastman Dental Hospitals
University College Hospital Grafton Way Building
Royal London Hospital for Integrated Medicine
University College Hospital Macmillan Cancer Centre
The Hospital for Tropical Diseases
University College Hospital at Westmoreland Street
We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women’s health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.
We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.